Roche’s an­ti-TIG­IT drug shows ze­ro re­sponse as monother­a­py — but da­ta back ef­fect for lung can­cer sub­set

Roche has post­ed some new, ear­ly-stage da­ta on its an­ti-TIG­IT drug tiragolum­ab in sol­id tu­mors that are be­ing stud­ied for fresh signs on the close­ly-watched class. And an­a­lysts won­der whether an ab­sence of any ef­fect as a monother­a­py — not good — will be out­weighed by added da­ta that their com­bo with their PD-L1 Tecen­triq works in a sub­set of lung can­cer pa­tients.

Among the 24 pa­tients signed up for the Phase Ia study us­ing es­ca­lat­ing dos­es of tiragolum­ab, none demon­strat­ed an ob­jec­tive re­sponse to the monother­a­py, ac­cord­ing to the ab­stract post­ed by AACR.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER